Improving Childhood Leukemia Treatment

  • Author: David Bradley
  • Published: 20 March 2012
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: ACS Chemical Biology/ACS Publications
thumbnail image: Improving Childhood Leukemia Treatment

There are about 5000 new cases of acute lymphoblastic leukemia (ALL) each year in the US making it the most common type of cancer in childhood. The enzyme terminal deoxynucleotidyl transferase (TdT), a specialized DNA polymerase, is a useful biomarker for ALL with about nine out of ten patients over-expressing this enzyme.


Researchers at Case Western Reserve University, Ohio, USA, have looked at two putative anti-leukemia compounds, the non-natural nucleotides 5-nitroindolyl-2′-deoxynucleoside triphosphate (5-NITP) and 3-ethynyl-5-nitroindolyl-2′-deoxynucleoside triphosphate (3-Eth-5-NITP) and their activity against TdT. Both compounds are active in laboratory tests against leukemia cells that over express TdT. The team suggests that the compounds might be useful theranostic agents for defining chemotherapy regimens more precisely in order to improve efficacy and reduce side-effects.


Article Views: 3632

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH